High-volume Hemofiltration in the Intensive Care Unit

A Blood Purification Therapy

Thomas Rimmelé, M.D., Ph.D.,* John A. Kellum, M.D., F.A.C.P., F.C.C.M.†

ABSTRACT

High-volume hemofiltration is an extracorporeal therapy that has been available in the intensive care unit for more than 10 yr. Recent improvements in technology have made its clinical application easier and safer. However, the definition, indications, and management of this technique are still unclear, and considerable controversy and confusion remain. The aim of this review is to analyze the available data while taking into account the distinction between two very different clinical situations: acute kidney injury requiring renal support, and severe inflammatory states where blood purification has been suggested as an adjuvant therapy. For patients with acute kidney injury requiring renal replacement therapy, the two largest multicenter studies performed to date established that high ultrafiltration flow rates are not necessary. Conversely, much experimental and some clinical evidence suggest that high-volume hemofiltration can be beneficial for the subset of critically ill patients with severe inflammatory states such as septic shock.

FOUR to 6% of critically ill patients undergo renal replacement therapy (RRT) because of acute kidney injury (AKI).1,2 Although the mortality rate for these patients can reach 60%,1 many aspects of the prescription of RRT and related management are still not well defined. Modality, timing of initiation, duration, anticoagulation strategy, and modifications in drug prescription remain controversial. Recent trials have helped to clarify RRT dosing for AKI,3,4 but concerns remain that some patients will not receive adequate intensity.5 Therefore, treatment of patients with AKI is very “practitioner-dependent” and thus highly heterogeneous, both nationally and internationally.6–8

Intermittent hemodialysis was the main RRT modality until the end of the 1970s, when continuous RRT was introduced. The solute transport principle on which hemodialysis is based is named diffusion, corresponding to a passive transfer of solutes through a semipermeable membrane, from blood to a dialysate along each solute’s concentration gradient. Solvent (plasma water) is not concerned with this phenomenon. The solute transport principle of hemofiltration is called convection, meaning that both plasma water and solutes are carried across the membrane by a hydrostatic pressure gradient. Plasma volume is then replaced by sterile electrolyte solutions, which are infused intravenously. Replacement fluid may be given before the hemofilter (predilution), after the hemofilter (postdilution), or a combination of both. This plasma water crossing the membrane is called ultrafiltrate, and it contains all the molecules from the plasma able to cross the membrane (molecular weight below the membrane cutoff). Figure 1 shows an illustration of what happens. The solute transport principle of hemodialysis is based on diffusion and convection are, along with a diagram of a hemodialysis circuit and a hemofiltration circuit. In 2012, although it has never been proven that continuous RRT provides better outcomes as compared with intermittent RRT,9,10 it is safe to say that continuous veno-venous hemofiltration (CVVH) has become the therapy of choice for critically ill patients requiring RRT, especially for those with hemodynamic instability.3,4,11 The recent large, prospective, European multicenter and observational DO-
RE-MI study reported that among patients treated with only one RRT modality (either continuous only or intermittent only), 82% received continuous RRT. This percentage tends to be similar in the United States and in Australia, and it does not seem that the type of intensive care unit (closed vs. open) plays a major role in the choice of the RRT modality. However, there is less consensus as to the application of high-volume hemofiltration (HVHF). This can easily be explained by the lack of clear evidence to guide application of HVHF during the last 20 yr. Thus, the aim of this review is to help clarify the situation by analyzing the available studies, taking into account the distinction between two very different clinical situations: AKI requiring renal support and severe inflammatory status requiring blood purification, and to examine whether HVHF might be useful in these situations. To achieve this goal, we conducted a systematic review of the COCHRANE and MEDLINE databases using PubMed with the following search terms: high-volume hemofiltration, acute kidney injury, blood purification, renal replacement therapy, and septic shock. The search included experimental and clinical studies, and we separated renal support for AKI from blood purification for systemic inflammation.

**Definition of High-volume Hemofiltration**

HVHF is not well defined in medical literature. Terms such as “high-volume,” “high intensity,” or “high flow” are used in publications for a large range of ultrafiltration flow rates, including some that by contemporary standards are not “high.” Additional confusion stems from the fact that the same given ultrafiltration flow rate can be evaluated both in the “high-volume” arm of one study and in the “low-volume” arm of another one. For example, in the Acute Renal Failure Trial Network study, 35 ml·kg⁻¹·h⁻¹ is the ultrafiltration flow rate for the group receiving the intensive therapy strategy, and, in the Boussekey et al. study, this ultrafiltration flow rate was used in the “low-volume” hemofiltration group.

In 2002, the Acute Dialysis Quality Initiative workgroup defined HVHF as more than 35 ml·kg⁻¹·h⁻¹. In 2012, this threshold is not universally accepted anymore, especially because, from a practical standpoint, 35 ml·kg⁻¹·h⁻¹ does not seem that high. Consequently, Honore´ and other experts recently updated and clarified the definition of HVHF. They agreed that HVHF includes continuous high-volume treatment of more than 50 ml·kg⁻¹·h⁻¹ 24 h a day and intermittent high-volume hemofiltration with brief, very high-volume treatment at 100–120 ml·kg⁻¹·h⁻¹ for a short period of 4–8 h, followed by conventional CVVH.
This latter strategy is also called “pulse HVHF” and was initially developed by Ronco et al. This definition is consistent with the 2001 Critical Care Nephrology conference held in Melbourne, Australia, where HVHF was defined as ultrafiltration flow rates greater than 50 ml·kg⁻¹·h⁻¹ and very HVHF for ultrafiltration flow rates greater than 100 ml·kg⁻¹·h⁻¹. At that time, it was also decided to universally use the “ml per kilogram per hour” as the unit to be used to express the ultrafiltration flow rate.

Renal Support

The question of the adequate dose for renal support in AKI patients requiring RRT was first illustrated in a landmark study by Ronco et al. in 2000. In this single-center Italian study, an ultrafiltration flow rate of 35 ml·kg⁻¹·h⁻¹ improved survival in AKI patients receiving postdilution CVVH, as compared with those who received 20 ml·kg⁻¹·h⁻¹. Nearly simultaneously, Schiffl et al. reported that intensive hemodialysis (performed daily) reduced mortality in patients with acute renal failure, as compared with conventional (alternate-day) intermittent hemodialysis. Consequently, at that time, a relationship between the dose of renal support prescribed and patient outcomes, including mortality, was highly suspected.

However, subsequent randomized controlled studies did not confirm these results. Bouman et al. found that survival and recovery of renal function were not different in 106 critically ill patients randomized in three different strategies of RRT: early HVHF, early low-volume hemofiltration, and late low-volume hemofiltration. Similarly, Tolwani et al. recently reported no difference in patient survival or renal recovery in 200 critically ill patients with AKI undergoing 35 ml·kg⁻¹·h⁻¹ versus 20 ml·kg⁻¹·h⁻¹ of continuous venovenous hemodiafiltration with prefilter replacement fluid. On the contrary, Saudan et al. published in 2006 interesting data suggesting that increasing dialysis dose by adding a dialysis component to CVVH increased survival. Indeed, in this trial that randomized 206 patients, the 28-day survival was significantly increased from 39% in the CVVH group to 59% in the continuous hemodiafiltration group (P = 0.03), and the 90-day survival were even more pronounced (34 vs. 59%, P = 0.0005).

So why did all these randomized controlled studies not find the same results? First, they are all relatively small, single-center studies (two centers for the Bouman study), and consequently, their results have limited external validity. It is well known that interventions tested in single clinical environments are not necessarily generalizable to a broader population, especially in critical care. Second, the trials were conducted by committed experts of RRT with a lack of blinding, increasing the risk of a possible Hawthorne effect (some patients belonging to one group consciously or unconsciously treated differently than the other). Third, AKI patients studied in these trials were drastically different. For example, the percentage of septic patients was below 15% in the Ronco study, whereas it was 60% in the Saudan study. Mortality rates in these studies were also very different, demonstrating the patients’ heterogeneity in terms of severity and consequently pointing out the difficulty in analyzing them collectively. In the Bouman study, survival at day 28 was indeed unusual, reaching 70%. Lastly, management of RRT was very different between these trials. Substitution fluid replacement was sometimes administered in postdilution (Bouman and Ronco studies) and sometimes in predilution (Saudan and Tolwani studies), therefore modifying the actual delivered dosage from the prescribed dosage. Furthermore, the percentage of patients achieving a delivered dosage greater than 80% of the prescribed dosage was not always provided.

In conclusion, if the physician’s singular goal is renal support through a RRT prescription for a patient with AKI, the...
best evidence currently available suggests that hemofiltration should be prescribed at 25 to 30 ml·kg⁻¹·h⁻¹.

Blood Purification for Systemic Inflammation

Pathophysiological Rationale

Systemic inflammatory states, such as severe sepsis and acute pancreatitis, are known to be major causes of AKI and other organ failures in critically ill patients.31 But they are also responsible for an important immunologic disturbance with the release into the bloodstream of numerous inflammatory mediators.32 Some aspects of this systemic inflammatory response may be beneficial to combat systemic infection, but when it is excessive, uncontrolled, or unbalanced, it has deleterious effects, including multiorgan failure and death. Indeed, inflammatory mediators such as cytokines have direct harmful effects on tissues (cytotoxic effects),33 and the prolonged release of antiinflammatory mediators, interpreted as a protective mechanism to prevent an excessive effect of the pro-inflammatory phase, leads to impaired immunity;34 this defect plays a major role in mortality.35,36 The overall concept of blood purification is therefore to attenuate this overwhelming systemic overflow of pro- and antiinflammatory mediators released at the early phase of sepsis and to restore a broad-based humoral homeostasis in order to improve outcome. A variety of mediators are involved in this inflammatory response, such as cytokines, chemokines, complement components, platelet-activating factor, leukotrienes, thromboxanes, and kinins.37 In the past, every attempt to modulate this inflammatory response by targeting one component has failed, at least at the clinical phase.38 Thus, the concept of blood purification has evolved toward a nonspecific removal of a large spectrum of inflammatory mediators.

Different pathophysiological theories have been proposed to support the concept of blood purification. First, Ronco and Bellomo hypothesized that shaving the cytokine peak concentration by removing them from the blood compartment during the early phase of sepsis could stop the inflammatory cascade, limit organ damage, and consequently decrease the incidence of multiorgan failure syndrome. This hypothesis is called the “peak concentration hypothesis.”39,40 More recently, Honoré proposed the “threshold immunomodulation hypothesis,” which takes a more dynamic view, postulating that the cytokine removal from the blood compartment leads to the removal of cytokines located at the tissue level because of an equilibration of their concentrations between these two compartments.41,42 This theory is interesting because it affects cytokines at the tissue level, which is where cytokines are harmful, and it also explains why numerous studies assessing blood purification techniques found an improvement of outcomes with no modification of cytokine blood concentrations as cytokines from the tissues replace those removed from the blood.43,44 Di Carlo and Alexander also proposed the “mediator delivery hypothesis,” in which HVHF is responsible for an increase of the lymphatic flow by 20- to 40-fold because of the high amounts of crystalloid fluids used for replacement with this technique.45-48 This leads to a significant drag and displacement of inflammatory mediators to the blood compartment, making them available for removal. In this theory, HVHF is therefore not only able to remove cytokines from the blood but also to insure that lymphatic transport from tissue and interstitium to the blood compartment occurs. Finally, Kellum has suggested that blood purification therapies act at the inflammatory cell level in order to restore the immune function through the regulation of monocytes and neutrophils.49-51 A novel component of this hypothesis is that by removing mediators from the plasma in the situation of systemic inflammation, one can restore the concentration gradient from plasma to infected tissues (fig. 2). This gradient has large effects on leukocyte trafficking and bacterial clearance.52 Thus the “cytokinetic model” may be more important than the cytotoxic models traditionally considered to explain the association between high cytokine levels and mortality. It needs to be acknowledged that neither of these different theories is based on robust data, and once discussed, they usually lead to subsequent questions. For example, do other extracorporeal blood purification techniques such as the use of endotoxin sorbents interfere with the inflammatory response in the same way as HVHF? It is wise to imagine that several different mechanisms may be responsible for the effects observed with these techniques. Moreover, because of the activation of leukocytes during the passage of blood through the artificial extracorporeal circuit, could HVHF interfere with the apoptotic or the leukocytic infiltration pathways of sepsis-induced AKI pathophysiology? Or, for the same reasons, could it be responsible for an aggravation of the tubular injury lesions observed in patients with septic-induced AKI, as recently hypothesized by Lerolle et al.?53

Regarding pathophysiology, HVHF is an attractive therapy in order to successfully remove a significant amount of a wide range of inflammatory molecules involved in the host inflammatory response. First, these circulating molecules are mostly water-soluble, and convection carries both plasma water and solutes across the membrane. Second, most inflammatory mediators are so-called “middle molecular weight molecules,” with a wide range of mass from 5 kDa to 60 kDa. Convection is far more effective than diffusion in removing middle molecules,54,55 at least with traditional membranes. Third, depending on their composition, most hemofiltration membranes also have some adsorptive properties. This associated principle corresponds to the saturable fixation of some molecules directly on the membrane along an affinity gradient depending on ionic, hydrophobic, and van der Waals interactions (fig. 3). The ultrafiltrate contains the molecules from the plasma that have a molecular weight below the membrane cutoff, and adsorption allows the removal of some molecules with a molecular weight higher than the membrane cutoff. Therefore, a very large panel of inflammatory mediators can be affected by hemofiltration. Finally, the use of HVHF is important because it has been
shown that conventional hemofiltration, with low ultrafiltration flow rates, is not effective for blood purification. Increasing the ultrafiltration flow rate may also increase the adsorption properties of the hemofilter because of its effect on transmembrane pressure (greater membrane site recruitment) and exposure of more of the internal matrix of the filter, thus increasing the available adsorptive surface area.

Animal Studies

Many animal studies have been performed to assess HVHF, especially in the 1990s, when HVHF was still very experimental in humans. Grootendorst et al. reported in 1992 an improvement in right ventricular function and the cardiac performance in 18 pigs with endotoxin-induced shock when zero balance HVHF (ultrafiltrate = 6,000 ml/h) was applied. He hypothesized that some vasoactive mediators, responsible for the myocardial depression, were removed with HVHF. Two years later, he also found in a gut ischemia and reperfusion porcine model that HVHF not only improved short-term hemodynamics, but also reduced macroscopic bowel damage observed at autopsy and improved 24-h survival. In an experimental pancreatitis model, HVHF improved hemodynamics, reversed sepsis–induced immunoparalysis, and increased 60-h survival. In addition, in this pancreatitis study, Yekebas et al. showed that survival rates were best with a very high ultrafiltration flow rate (100 ml · kg$^{-1}$ · h$^{-1}$) and frequent filter changes (every 12 h). Rogiers et al. found similar results in dogs with endotoxin-induced shock, showing an improved cardiac performance when HVHF was performed with polyacrylonitrile membranes compared with polysulfone membranes. However, these effects that are supposed to be related to the adsorption properties of the membrane are temporary because of saturation phenomenon.

Some animal studies assessed HVHF by looking at ultrafiltrate obtained from either healthy donor or septic donor animals and infused into a healthy acceptor animal. The ability for HVHF to remove toxic mediators is suggested
when ultrafiltrate obtained from septic animals leads to hemodynamic disturbances or even death in healthy animals. In 2000, Honore et al. reported a reduction of the mortality rate from 79% (expected mortality based on APACHE II and SAPS II scores) to 55%. A few years later, Joannes-Boyau et al. obtained a similar result with a predicted 28-day mortality of 70% and an observed mortality of 46% in a study assessing the effect of 40–60 ml·kg⁻¹·h⁻¹ maintained for 96 h in patients with septic shock and multiorgan dysfunction syndrome. In addition, Ratanarat et al. reported a reduction of the 28-day mortality rate from 70% (predicted) to 47% (observed) when septic patients underwent daily pulse HVHF.

In patients without sepsis but with systemic inflammation, the effect of HVHF on mortality was evaluated in two randomized controlled trials. The largest study assessing mortality with HVHF in randomized patients was performed on 61 resuscitated cardiac arrest patients. This whole-body ischemia-reperfusion represents an interesting "sepsis-like" syndrome. Although the primary analysis was negative, after adjusting for imbalances in baseline characteristics, very HVHF (200 ml·kg⁻¹·h⁻¹ during 8 h) was associated with improved 6-month survival (logistic regression odds ratio, 4.4; 95% CI, 1.1–16.6) and a decreased risk of death from early intractable shock. Similarly, in 37 patients with acute pancreatitis, hemodynamics and short-time survival rates were significantly better with HVHF (4 l/h) than in patients receiving low-volume hemofiltration (1 l/h). The most important recent studies assessing mortality with HVHF as a blood purification therapy are summarized in table 1.

Unlike these promising results using HVHF, standard "renal dose" continuous RRT appears to be ineffective as an immune-modulating therapy. In 1998, Kellum et al. found modest effects of CVVH (2 l/h) compared with continuous hemodialysis on tumor necrosis factor and interleukin-6 in a population with acute kidney injury. Reduction of immune-modulating therapy. In 1998, Kellum et al. found modest effects of CVVH (2 l/h) compared with continuous hemodialysis on tumor necrosis factor and interleukin-6 in a population with acute kidney injury. Reduction of inflammatory mediators and on organ dysfunctions in 24 septic patients without AKI. In this randomized controlled trial, CVVH was not associated with a reduction in any plasma cytokine concentrations and did not decrease organ dysfunctions, as compared with no hemofiltration. Recently, Payen et al. found similar results (and even a trend toward worse outcomes) in septic shock patients without AKI who underwent CVVH (25 ml·kg⁻¹·h⁻¹ for a 96-h period) at the early phase of sepsis compared with those who were managed conventionally. This study confirmed that low-volume hemofiltration (standard continuous RRT) is not a suitable technique for blood purification in sepsis but, as the authors stated in their conclusion, it did not rule out a beneficial effect of HVHF on the course of sepsis.
Alternatives to HVHF for Blood Purification

Other extracorporeal blood purification therapies are currently available besides HVHF. Indeed, coupled plasma filtration adsorption, polymyxin-B hemoperfusion, and the use of high cutoff membranes have also been proposed as adjuvant treatments for sepsis.\textsuperscript{7,8}–\textsuperscript{80} However, at this time, it is not possible to state which technique is most effective, because they have not been compared with each other so far. Nevertheless and interestingly, some additional hybrid techniques can synergistically combine HVHF and hemoadsorption in a technique named “high adsorptive hemofiltration.”\textsuperscript{81}

This therapy consists of optimizing the performances of the hemofilters regarding cytokine and/or endotoxin removal through hemoadsorption by manipulating their composition or structure. For example, positive hemodynamic effects of a polyacrylonitrile hemofiltration membrane having endotoxin adsorption properties were recently reported in septic pigs.\textsuperscript{81} The membrane surface polarity was modified by the addition of a polyethyleneimine coating, a positively charged polymer, allowing the membrane to catch negatively charged endotoxins via surface adsorption (fig. 4). In the same line, other models where HVHF and high-permeability

---

**Table 1. Most Important Recent Human Studies that Assessed the Effects of HVHF as a Blood Purification Technique on Hemodynamics and Survival**

<table>
<thead>
<tr>
<th>Design</th>
<th>First Author, Year</th>
<th>Number of Patients</th>
<th>Clinical Setting</th>
<th>Dose (ml \cdot kg(^{-1}) \cdot h(^{-1}))</th>
<th>Improved Hemodynamics with HVHF</th>
<th>Improved Survival with HVHF</th>
<th>(P) Value (Survival)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized, controlled trials</td>
<td>Laurent, 2005\textsuperscript{75}</td>
<td>61</td>
<td>Resuscitated cardiac arrest</td>
<td>200</td>
<td>Yes</td>
<td>Yes; 6-mo survival: 21–45%</td>
<td>0.026</td>
</tr>
<tr>
<td></td>
<td>Jiang, 2005\textsuperscript{77}</td>
<td>37</td>
<td>Severe acute pancreatitis</td>
<td>4,000 ml/h</td>
<td>Yes</td>
<td>Yes; 14-day survival: 68.4–94.4%</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td></td>
<td>Boussekey, 2008\textsuperscript{14}</td>
<td>20</td>
<td>Septic shock</td>
<td>65</td>
<td>Yes</td>
<td>No</td>
<td>0.65</td>
</tr>
<tr>
<td></td>
<td>IVOIRE study, on going Cole, 2001\textsuperscript{58}</td>
<td>(\approx 150)</td>
<td>Septic shock</td>
<td>70</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Randomized, crossover trial</td>
<td>Honoré, 2000\textsuperscript{70}</td>
<td>20</td>
<td>Septic shock with multiorgan failure</td>
<td>6,000 ml/h</td>
<td>Yes</td>
<td>Not assessed</td>
<td>N/A</td>
</tr>
<tr>
<td>Prospective, cohort, uncontrolled trials</td>
<td>Joannes-Boyau, 2004\textsuperscript{71}</td>
<td>24</td>
<td>Septic shock</td>
<td>40–60</td>
<td>Yes</td>
<td>Yes; 28-day survival: (Expected) 45%</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td>Ratanarat, 2005\textsuperscript{74}</td>
<td>15</td>
<td>Severe sepsis</td>
<td>85 (pulse HVHF)</td>
<td>Yes</td>
<td>Yes; 28-day survival: (Expected) 30%–54%</td>
<td>&lt;0.075</td>
</tr>
<tr>
<td></td>
<td>Cornejo, 2006\textsuperscript{69}</td>
<td>20</td>
<td>Refractory septic shock</td>
<td>100</td>
<td>Yes</td>
<td>Yes; Hospital survival: (Expected) 53%</td>
<td>N/A</td>
</tr>
<tr>
<td>Retrospective trials</td>
<td>Piccinni, 2006\textsuperscript{73}</td>
<td>80</td>
<td>Septic shock</td>
<td>45</td>
<td>Yes</td>
<td>Yes; 28-day survival: 60%</td>
<td>&lt;0.03</td>
</tr>
<tr>
<td></td>
<td>Zhu, 2009\textsuperscript{88}</td>
<td>63</td>
<td>Severe acute pancreatitis</td>
<td>60–80</td>
<td>No</td>
<td>Yes; 28-day survival: 65.5–91.2%</td>
<td>0.014</td>
</tr>
</tbody>
</table>

HVHF = high-volume hemofiltration.
hemofiltration work synergistically have shown promising results. \(^8^2\)

**Clinical Use of HVHF**

Although new machines dedicated for RRT or blood purification are more reliable with very sensitive and precise pressure control and volume balance functions, the use of HVHF still requires attention to several technical aspects. First, in order to keep filtration fraction below 25%, the blood flow rate has to be increased. This consequently requires the use of large dialysis catheters with diameters such as 13.5–15 French inserted in an adequate location, the right jugular site perhaps being the best.\(^8^3\) Second, the optimal pre- and post-dilution ratio for replacement fluid is suggested to be 1/3–2/3 by some experts.\(^1^7\) Indeed, a good compromise between the loss of efficacy because of predilution and its benefit regarding blood rheology conditions is suitable, although data addressing this particular aspect are limited.\(^8^4\) Third, to date, no recommendation about anticoagulation can be made because of the lack of evidence of any superiority of any one strategy. However, citrate is increasingly employed because of its advantages in terms of filter lifetime and coagulation. Fourth, highly biocompatible synthetic membranes with a high exchange surface of at least 2 m\(^2\) are suitable.\(^1^7\) Fifth, temperature monitoring must be performed very closely because of the greater heat loss observed with high convective exchanges and the subsequent risk of hypothermia. Sixth, HVHF may be responsible for an important loss of small beneficial molecules including nutrients, amino-acids, vitamins, trace elements, and antimicrobials in the ultrafiltrate.\(^8^5,8^6\) Thus, nutritive supplementation (e.g., glutamine) and adaptation of drug prescriptions must be taken into account.\(^8^7\) Antibiotics levels in particular should be checked whenever possible. When using pulse HVHF, it is therefore advisable to dose around the procedure, much the same way drugs are managed in intermittent hemodialysis. For the same reason, strict monitoring of sodium, potassium, phosphorus, glucose, and acid-base balance is mandatory.\(^1^7\)

Regarding safety, it is also important to recall that HVHF is usually performed in patients with a multiorgan failure syndrome, and therefore the adverse effects of the therapy are exacerbated by the severity of these patients. HVHF has the same risks as other extracorporeal therapies such as bleeding related to anticoagulation, infection, gas embolism, and hemodynamic intolerance, but the use of high fluid exchanges multiplies the risk of metabolic consequences if there is an error in the replacement fluid composition. In other words, physicians have to be aware that a small mistake in the therapy prescription can rapidly have major deleterious consequences. Finally, the difference between the prescribed and delivered dose can rapidly become important with HVHF if the therapy is interrupted for some reason (nursing activities, coagulation issues, transfer to the operating room, or radiology).

**Conclusion**

Physicians initiating RRT should first identify their goals. If the strategy is to support renal function, then HVHF is not necessary and ultrafiltration flow rates ranging from 25 to 30 ml·kg\(^{-1}\)·h\(^{-1}\) seem adequate in order to reach the optimal delivered dose of 20–25 ml·kg\(^{-1}\)·h\(^{-1}\). For blood purification in sepsis, the dose-response relationship may be very different and high-volume hemofiltration may be considered.

Physicians initiating RRT should first identify their goals. If the strategy is to support renal function, then HVHF is not necessary and ultrafiltration flow rates ranging from 25 to 30 ml·kg\(^{-1}\)·h\(^{-1}\) seem adequate in order to reach the optimal delivered dose of 20–25 ml·kg\(^{-1}\)·h\(^{-1}\). For blood purification in sepsis, the dose-response relationship may be very different and high-volume hemofiltration may be considered.
mechanism by which blood purification therapies work on modulating the cytotoxic and cytokinetic effects of inflammatory mediators is still unclear, we believe that basic science studies are still warranted. In addition, more clinical trials conducted in both mono- and multicenters are suitable in order to evaluate the ability of HVHF to improve clinical outcomes (i.e., mortality or organ failure) rather than to study surrogate markers (i.e., inflammatory mediator clearance or physiologic variables such as oxygenation and hemodynamics).

References


27. Bellomo R: Do we know the optimal dose for renal replacement therapy in the intensive care unit? Kidney Int 2006; 70:1202–4


regarding rationale, therapeutic target and dose of hemofil-
tration and hybrid therapies in septic acute kidney injury.
Blood Purif 2011; 33:44–51
31. Hoste EA, Schurgers M: Epidemiology of acute kidney injury:
How big is the problem? Crit Care Med 2008; 36:5146–51
32. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky
MR, Fine J, Krichevsky A, Delude RL, Angus DC, GenIMS
Investigators: Understanding the inflammatory cytokine re-
sponse in pneumonia and sepsis: Results of the Genetic and
Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern
33. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castillo-
Cortes A, Brunner MD, Panoskaitis N: Cytokine storm in a
phase 1 trial of the anti-CD28 monoclonal antibody
34. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA:
The sepsis seecaw: Tilting toward immunosuppression. Nat
35. Adib-Couquy M, Cavaillon JM: Compensatory anti-inflamma-
36. Turnbull IR, Clark AT, Stromberg PE, Dixon DJ, Woolsey CA,
Davis CG, Hotchkiss RS, Buchman TG, Coopersmith CM:
Effects of aging on the immunopathologic response to se-
37. Tetta C, Bellomo R, Inguggiato P, Warrten ML, Ronco C:
Endotoxin and cytokine removal in sepsis. Ther Apher 2002;
6:109–15
38. Bone RC, Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care
Med 1996; 24:1125–8
39. Bone RC, Bellomo R, Tetta C, Warrten ML, Ronco C:
Continuous venovenous hemofiltration improves the
metabolism by continuous venovenous hemofiltration in ex-
perimental porcine pancreatitis. Crit Care Med 2001;
29:1423–30
40. Yekebas EF, Eisenberger CF, Ohnserose H, Saalmuller A,
T, Busch C, Knoefel WT, Bloechle C, Izbicki JR: Attenuation of
sepsis-related immunoparalysis by continuous veno-
venous hemofiltration in experimental porcine pancreatitis.
Crit Care Med 2001; 29:1423–30
41. Call DR, Nemzcek JA, Ebong SJ, Bolgos GL, Newcomb DE,
Remick DG: Ratio of local to systemic chemokine concen-
trations regulates neutrophil recruitment. Am J Pathol 2001;
158:715–21
42. De Vries RC, Vanholder RC, Pascual M, Lameire NH, Colar-
dyn FA: Can inflammatory cytokines be removed efficiently
by continuous renal replacement therapies? Intensive Care
43. Bellomo R, Tetta C, Mariano F, Wratten ML, Bonello M, Bor-
doni V, Cardona X, Inguggiato P, Pilotto L, d’Intini V,
Bellomo R: Impacting the mechanisms of continuous renal
replacement therapy in sepsis: The peak concentration hy-
pothesis. Artif Organs 2003; 27:792–801
44. Honore PM, Joannes-Boyau O: High volume hemofiltration
(HVHF) in sepsis: A comprehensive review of rationale,
clinical applicability, potential indications and recommenda-
45. Honore PM, Matson JR: Extracorporeal removal for sepsis:
Acting at the tissue level—the beginning of a new era for
this treatment modality in septic shock. Crit Care Med 2004;
32:896–7
46. Honore PM, Joannes-Boyau O, Gressens B: Blood and plasma
treatments: The rationale of high-volume hemofiltration.
Contrb NephroI 2007; 156:387–95
47. Klouoke K, Cavadore P, Portales P, Clot J, Canaud B, Béraud
JJ: Continuous venous-venous hemofiltration improves hemo-
dynamics in septic shock with acute renal failure without
modifying TNFalpha and IL6 plasma concentrations. J Nep-
hol 2002; 15:150–7
48. Di Carlo JV, Alexander SR: Hemofiltration for cytokine-
driven illnesses: The mediator delivery hypothesis. Int J Artif
Organs 2005; 28:777–86
49. Olczewski WJ: The lymphatic system in body homeostasis:
50. Onarheim H, Missavage AE, Gunther RA, Kramer GC, Reed
RK, Laurent TC: Marked increase of plasma hyaluronan after
50:259–65
51. Wasserman K, Mayerson HS: Dynamics of lymph and plasma
Contrb NephroI 2010; 165:322–8
Digitio A, Dan M, Irene M, La Greca G, Inguggiato P, Mag-
giore U, De Nitti C, Warrten ML, Ricci Z, Tetta C: A pilot
study of coupled plasma filtration with adsorption in septic
54. Yekebas EF, Eisenberger CF, Ohnserose H, Saalmuller A,
T, Busch C, Knoefel WT, Bloechle C, Izbicki JR: Attenuation of
sepsis-related immunoparalysis by continuous veno-
venous hemofiltration in experimental porcine pancreatitis.
Crit Care Med 2001; 29:1423–30
55. Call DR, Nemzcek JA, Ebong SJ, Bolgos GL, Newcomb DE,
Remick DG: Ratio of local to systemic chemokine concen-
trations regulates neutrophil recruitment. Am J Pathol 2001;
158:715–21
56. Di Carlo JV, Alexander SR: Hemofiltration for cytokine-
driven illnesses: The mediator delivery hypothesis. Int J Artif
Organs 2005; 28:777–86
57. Honore PM, Joannes-Boyau O, Gressens B: Blood and plasma
treatments: The rationale of high-volume hemofiltration.
Contrb NephroI 2007; 156:387–95
JJ: Continuous venous-venous hemofiltration improves hemo-
dynamics in septic shock with acute renal failure without
modifying TNFalpha and IL6 plasma concentrations. J Nep-
hol 2002; 15:150–7
59. Wasserman K, Mayerson HS: Dynamics of lymph and plasma
Contrb NephroI 2010; 165:322–8


84. Ricci Z, Ronco C: Pre- versus post-dilution CVVH. Blood Purif 2005; 23:338


